Galen is Proud to Support Research by Brigham and Women’s Hospital
The team led by Professor Bernstein, a neurologist at Brigham and Women’s Hospital and an associate professor of neurology at Harvard Medical School, are investigating the safety and efficacy of a monoclonal antibody for menstrual related migraines.
Menstrual migraine is a migraine that is directly related to changes in hormone levels, specifically fluctuations in estrogen. These migraines are debilitating and have a huge impact on a person’s quality of life.
Galen is proud to support this research by providing our Migraine-Specific Quality of Life measure (MSQoL). Rasch transform scores have been provided from the measure enhancing the precision of the data collected, making subtle differences in improvement more detectable. The study also aims to establish the Minimal Clinically Important Difference (MCID) for the measure helping to determine the smallest change that a patient would perceive as meaningful and beneficial to them.
Patient recruitment is well underway, and we are excited to hear how the results from this study build on the existing evidence for preventative migraine medication. Research like this is a vital step toward providing some much-needed relief for those experiencing recurrent menstrual migraines.
If you are interested in the study, here is the link for more information; https://lnkd.in/dsnY8bT3